- Preliminary results to be presented at conference on medical health disorders in Cambridge, UK in September
Perth, Australia & Malta – 29 May 2017 – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), developer of quality medical solutions in the neuroscience space, is pleased to advise that the clinical trial for Mente Autism (“Clinical Trial”) has progressed as planned with investigators now approaching the end of the 12-week therapy session for the initial cohort of subjects.
The Clinical Trial, which is being independently conducted by the Carrick Institute in Florida, USA, aims to investigate Mente Autism as a therapy for children aged between 3 and 12 years on the autism spectrum. Subjects are being progressively onboarded to Mente Autism to commence 12 weeks of at home therapy, and the initial subjects will start to conclude this therapy shortly.
Based on the advice of lead investigator Prof. Frederick Carrick, the preliminary findings of the study are expected to be ready for presentation at the University of Cambridge world conference on mental health disorders in September this year.
Prof. Carrick said: “The randomised placebo controlled trial of the Mente Autism device is currently ongoing in Orlando, Florida. Subjects with diagnosed Autism Spectrum Disorder from throughout the United States have been randomised into a treatment group and a sham group. These groups have been entered into a 12-week at home therapy investigation using the Mente Autism device. Investigators report that they are approaching the end of the 12-week therapy session for the initial cohort of subjects.”
For more information about Neurotech and Mente Autism please visit: http://www.neurotechinternational.com. http://www.mentetech.com.
Click here for the full ASX announcement
For more information please contact:
Matthew Wright
matt@nwrcommunications.com.au
Tel: +61 451 896 420
About Neurotech
Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism. For more information, visit: http://www.neurotechinternational.com
Neurotech International Ltd
ABN 73 610 205 402
Level 14, 191 St Georges Terrace
Perth, Western Australia 6060
www.neurotechinternational.com
Perth, Australia & Malta – 29 May 2017 – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), developer of quality medical solutions in the neuroscience space, is pleased to advise that the clinical trial for Mente Autism (“Clinical Trial”) has progressed as planned with investigators now approaching the end of the 12-week therapy session for the initial cohort of subjects.
The Clinical Trial, which is being independently conducted by the Carrick Institute in Florida, USA, aims to investigate Mente Autism as a therapy for children aged between 3 and 12 years on the autism spectrum. Subjects are being progressively onboarded to Mente Autism to commence 12 weeks of at home therapy, and the initial subjects will start to conclude this therapy shortly.
Based on the advice of lead investigator Prof. Frederick Carrick, the preliminary findings of the study are expected to be ready for presentation at the University of Cambridge world conference on mental health disorders in September this year.
Prof. Carrick said: “The randomised placebo controlled trial of the Mente Autism device is currently ongoing in Orlando, Florida. Subjects with diagnosed Autism Spectrum Disorder from throughout the United States have been randomised into a treatment group and a sham group. These groups have been entered into a 12-week at home therapy investigation using the Mente Autism device. Investigators report that they are approaching the end of the 12-week therapy session for the initial cohort of subjects.”
For more information about Neurotech and Mente Autism please visit: http://www.neurotechinternational.com. http://www.mentetech.com.
Click here for the full ASX announcement
For more information please contact:
Matthew Wright
matt@nwrcommunications.com.au
Tel: +61 451 896 420
About Neurotech
Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism. For more information, visit: http://www.neurotechinternational.com
Neurotech International Ltd
ABN 73 610 205 402
Level 14, 191 St Georges Terrace
Perth, Western Australia 6060
www.neurotechinternational.com
